QSAM Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 17, 2022 08:00 ET | QSAM Biosciences Inc.
Dosed First Patient in Phase 1 Clinical Program Evaluating CycloSam® Radiopharmaceutical Drug Candidate for Treatment of Metastatic Bone Cancer Austin, TX, May 17, 2022 (GLOBE NEWSWIRE) -- QSAM...
20170406 Telix Logo.png
Telix Radiopharmaceutical Production Facility Buildout Commences
March 21, 2022 18:41 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development...
QSAM Biosciences Appoints Adriann Sax to Board of Directors
January 25, 2022 08:30 ET | QSAM Biosciences Inc.
Austin, TX, Jan. 25, 2022 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
RAFA To Add Major Component to the Tashkent Pharma Park
December 17, 2021 11:34 ET | RAFARMA PHARMACEUTICALS INC
Nicosia, Cyprus, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) and the Czech company “Block” signed an agreement on the implementation of the construction of a...
Radiotherapy Market Size Worth $10,170.80 Million, Globally, by 2028 at 5.9% CAGR - Exclusive Report by The Insight Partners
December 16, 2021 13:44 ET | The Insight Partners
New York, Dec. 17, 2021 (GLOBE NEWSWIRE) -- According to the new market research report "Radiotherapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (External-Beam Radiation...
Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology
October 18, 2021 16:00 ET | Crinetics Pharmaceuticals, Inc.
Co-founded by Crinetics, 5AM Ventures and Frazier Healthcare Partners, the New Company Launches with $30M in Initial Financing Provided by 5AM and Frazier Pipeline is Built from Crinetics’ Core...
Radiopharmaceuticals Market ($13.81Bn by 2028) Growth Forecast at 9% CAGR During (2021-2028) - COVID-19 Impact and Global Analysis by TheInsightPartners.com
August 24, 2021 15:06 ET | The Insight Partners
New York, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Radiopharmaceuticals Market: Key InsightsAccording to our new research study on “Radiopharmaceuticals Market to 2028 – Global Analysis and Forecast – by...
Rafarma’s Global Pharmaceutical Strategy At A Glance
Nicosia, Cyprus, May 18, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is an international biotechnological and pharmaceutical company that combines research centers and modern...
Vivos Inc. Provides 2020 Recap and Outlines 2021 Objectives
January 28, 2021 09:30 ET | Vivos Inc.
Richland WA, Jan. 28, 2021 (GLOBE NEWSWIRE) --  Vivos Inc. (OTCQB: RDGL), provides 2020 recap and outlines future objectives. Vivos’ CEO, Dr. Mike Korenko stated, “as we begin 2021, I think it is...
Rise in Radioligand Therapies to Drive Global Radiopharmaceuticals Market till 2023: WiseGuyReports
June 11, 2019 09:09 ET | WiseGuy Research Consultants Pvt. Ltd.
Pune, India, June 11, 2019 (GLOBE NEWSWIRE) -- Radiopharmaceuticals are a group of compounds used for discerning the presence of abnormalities in tissues, organs, or cells. They are a vital...